Veeva Systems (NYSE: VEEV) shares moved above a $296.24 flat-base buy point, putting the stock in a technical buy range and drawing renewed attention to healthcare software. The shares rose 2% on Tuesday to close at $301.63, their highest close since October 8, 2005. They later pulled back but remained within 5% of the buy point.
Veeva is on the IBD 50 list of growth stocks and has a Composite Rating of 99, reflecting strong relative scores across earnings, price performance and other technical measures. The rating and chart pattern do not determine future business results, which will depend on revenue growth, customer demand and broader market conditions.
Veeva and IQVIA expand clinical operations partnership
Tuesday’s advance followed an announcement that Veeva and IQVIA (NYSE: IQV) would broaden their work together in clinical research operations. The companies plan to expand cooperation across clinical operations applications. Veeva provides software for the life sciences industry, while IQVIA serves the clinical research, data and healthcare analytics markets. The expanded agreement points to a concrete area of demand for healthcare software.
The companies previously had a protracted intellectual property dispute. They reached an agreement last year to end the years-long legal conflict. With the dispute settled, attention has shifted to the practical use of clinical operations software and the commercial scope of their partnership.
Earnings and guidance helped set up the breakout
The $296.24 buy point took shape on August 27. Veeva then began a 15.2% advance after its second-quarter results significantly exceeded market expectations and it raised its full-year revenue guidance. The reported information did not specify the size of the earnings beat or the revised revenue target, but the improved outlook provided a fundamental backdrop for the stock’s subsequent consolidation and advance.
Veeva later formed a flat base before breaking above resistance on Tuesday. The pattern involves a period of trading in a relatively narrow range before an attempt to move higher. The shares retreated on Wednesday but stayed above the buy point. That leaves the breakout intact for now, though further trading and volume would help show whether buying demand can sustain it.
Investors watch healthcare software and AI applications
Veeva is viewed as a prominent company in healthcare software and AI applications. As life sciences companies digitize clinical trials, demand could extend to software for clinical operations, data management and workflows. Whether the expanded IQVIA partnership translates into orders, greater customer usage and revenue growth will be a more meaningful measure of its commercial value than a single share-price breakout.
As of October 14, Veeva shares remained near the technical buy point. Investors are watching subsequent earnings, any further changes to full-year revenue guidance and whether the expanded partnership produces measurable business contributions. The figures disclosed so far include a $301.63 close, a $296.24 buy point, a prior 15.2% advance, and second-quarter results that beat expectations alongside a higher full-year revenue outlook.